Evidence map›Paper›PMID 36034139›Full record

ArticleFrontiers in aging neuroscience2022

Deep learning of MRI contrast enhancement for mapping cerebral blood volume from single-modal non-contrast scans of aging and Alzheimer's disease brains.

Chen Liu, Nanyan Zhu, Haoran Sun, Junhao Zhang, Xinyang Feng, Sabrina Gjerswold-Selleck, Dipika Sikka, Xuemin Zhu, Xueqing Liu, Tal Nuriel and 7 more

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chen LiuDepartment of Electrical Engineering, Columbia University, New York, NY, United States.
Nanyan ZhuDepartment of Biological Sciences, Columbia University, New York, NY, United States.
Haoran SunDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Junhao ZhangDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Xinyang FengDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Sabrina Gjerswold-SelleckDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Dipika SikkaDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Xuemin ZhuDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Xueqing LiuDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Tal NurielDepartment of Radiation Oncology, Columbia University, New York, NY, United States.
Hong-Jian WeiDepartment of Radiation Oncology, Columbia University, New York, NY, United States.
Cheng-Chia WuDepartment of Radiation Oncology, Columbia University, New York, NY, United States.
J Thomas VaughanDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Andrew F LaineDepartment of Biomedical Engineering, Columbia University, New York, NY, United States.
Frank A ProvenzanoDepartment of Neurology, Columbia University, New York, NY, United States.
Scott A SmallDepartment of Neurology, Columbia University, New York, NY, United States.
Jia GuoDepartment of Psychiatry, Columbia University, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While MRI contrast agents such as those based on Gadolinium are needed for high-resolution mapping of brain metabolism, these contrast agents require intravenous administration, and there are rising concerns over their safety and invasiveness. Furthermore, non-contrast MRI scans are more commonly performed than those with contrast agents and are readily available for analysis in public databases such as the Alzheimer's Disease Neuroimaging Initiative (ADNI). In this article, we hypothesize that a deep learning model, trained using quantitative steady-state contrast-enhanced structural MRI datasets, in mice and humans, can generate contrast-equivalent information from a single non-contrast MRI scan. The model was first trained, optimized, and validated in mice, and was then transferred and adapted to humans. We observe that the model can substitute for Gadolinium-based contrast agents in approximating cerebral blood volume, a quantitative representation of brain activity, at sub-millimeter granularity. Furthermore, we validate the use of our deep-learned prediction maps to identify functional abnormalities in the aging brain using locally obtained MRI scans, and in the brain of patients with Alzheimer's disease using publicly available MRI scans from ADNI. Since it is derived from a commonly-acquired MRI protocol, this framework has the potential for broad clinical utility and can also be applied retrospectively to research scans across a host of neurological/functional diseases.

Indexed as

agingAlzheimer's diseaseCBVdeep-learninggadoliniumMRI

Identifiers

PMID36034139
PMCPMC9407020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.